Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LBPHNASDAQ:RZLTNASDAQ:SLSNASDAQ:YMTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$18.01+5.9%$20.20$3.60▼$28.15$612.29M1.24363,556 shs502,214 shsRZLTRezolute$3.30+1.9%$2.00$0.72▼$3.63$130.01M1.29275,089 shs278,502 shsSLSSELLAS Life Sciences Group$1.52+7.8%$1.11$0.50▼$1.91$79.34M2.351.60 million shs1.58 million shsYMTXYumanity Therapeutics$0.49+4.3%$1.19$0.95▼$13.23$5.28M0.32473,083 shs838,282 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals+5.94%-11.93%-12.57%-26.28%+146.04%RZLTRezolute+1.85%+26.92%+73.68%+230.03%+72.77%SLSSELLAS Life Sciences Group+7.80%+8.57%+44.76%+188.70%-2.56%YMTXYumanity Therapeutics+3.43%+10.48%-12.70%-82.13%-90.22%Bitcoin Rockets To Record High But Buy THIS Instead (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLBPHLongboard Pharmaceuticals1.4675 of 5 stars3.51.00.00.02.62.50.0RZLTRezolute3.0923 of 5 stars3.53.00.00.03.84.20.0SLSSELLAS Life Sciences Group0.7314 of 5 stars3.52.00.00.01.10.00.0YMTXYumanity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals3.00Buy$39.50119.32% UpsideRZLTRezolute3.00Buy$8.80166.67% UpsideSLSSELLAS Life Sciences Group3.00Buy$3.0097.37% UpsideYMTXYumanity TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest YMTX, RZLT, LBPH, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/16/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.004/10/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/15/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/13/2024LBPHLongboard PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$32.003/13/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/16/2024LBPHLongboard PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.002/14/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/ARZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/ASLSSELLAS Life Sciences Group$1M85.53N/AN/A($0.25) per share-6.08YMTXYumanity Therapeutics$4.84M1.09N/AN/A$2.28 per share0.21Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.38N/AN/AN/AN/A-97.53%-85.21%5/14/2024 (Estimated)RZLTRezolute-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)SLSSELLAS Life Sciences Group-$37.34M-$1.36N/A∞N/AN/A-2,405.54%-241.00%5/9/2024 (Estimated)YMTXYumanity Therapeutics-$39.50M-$3.00N/A∞N/A-660.61%-263.34%-107.08%N/ALatest YMTX, RZLT, LBPH, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023LBPHLongboard Pharmaceuticals-$0.60-$0.62-$0.02-$0.62N/AN/A2/13/2024Q2 2024RZLTRezolute-$0.27-$0.27N/A-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/AYMTXYumanity TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A5.145.14RZLTRezoluteN/A12.0012.00SLSSELLAS Life Sciences GroupN/A0.230.23YMTXYumanity TherapeuticsN/A2.212.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%RZLTRezolute82.97%SLSSELLAS Life Sciences Group17.38%YMTXYumanity Therapeutics25.10%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals5.57%RZLTRezolute18.20%SLSSELLAS Life Sciences Group1.60%YMTXYumanity Therapeutics12.45%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals5036.02 million34.01 millionOptionableRZLTRezolute5740.13 million32.83 millionNot OptionableSLSSELLAS Life Sciences Group1756.27 million55.37 millionNot OptionableYMTXYumanity Therapeutics4010.86 million9.50 millionNot OptionableYMTX, RZLT, LBPH, and SLS HeadlinesSourceHeadlineJSPR Jasper Therapeutics, Inc.seekingalpha.com - March 20 at 7:11 PMCara Therapeutics Inc CARAmorningstar.com - November 3 at 7:42 AMYumanity Therapeutics Inc.thestreet.com - October 6 at 6:24 PMFormer Onyx CEO Returns to Biotech to Launch Boston Start Upthestreet.com - July 5 at 1:02 AMKineta raises $6M through registered direct offeringbizjournals.com - May 1 at 1:51 AMColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus Reportsfinance.yahoo.com - February 22 at 10:00 AMYumanity Therapeutics's Return On Capital Employed Insightsmsn.com - December 26 at 1:21 PMKineta finalizes reverse merger with Yumanity, secures additional fundingbizjournals.com - December 20 at 6:58 PMYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ...bakersfield.com - December 5 at 6:26 PMYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kinetafinance.yahoo.com - December 5 at 6:26 PMWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?investorplace.com - December 5 at 3:03 PMYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developmentsfinanznachrichten.de - November 14 at 11:42 AMYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developmentsfinance.yahoo.com - November 14 at 11:42 AMYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.finance.yahoo.com - November 10 at 4:45 PMYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kinetafinance.yahoo.com - August 29 at 10:16 AMYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developmentsfinance.yahoo.com - August 4 at 6:52 PMGlioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless Opportunitiesmedgadget.com - July 14 at 1:51 AMYUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of…lawyer-monthly.com - July 5 at 10:55 PMInside Kineta's plans after unveiling reverse merger dealfinance.yahoo.com - June 8 at 9:39 PMSeattle biotech Kineta to go public in merger deal with Yumanity Therapeuticsbizjournals.com - June 7 at 11:47 PMShort Volatility Alert: Yumanity Therapeutics, Inc.msn.com - June 7 at 6:47 PMYumanity leaps as it reveals Janssen asset purchase and merger deal with Kinetathepharmaletter.com - June 6 at 5:23 PMYumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTXmarketwatch.com - June 6 at 12:23 PMYumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26Mseekingalpha.com - June 6 at 12:23 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsLongboard PharmaceuticalsNASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.SELLAS Life Sciences GroupNASDAQ:SLSSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.Yumanity TherapeuticsNASDAQ:YMTXYumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.